Lars Röse
9Patents
0h-index
29Co-inventors
37Inventor score
Filing activity: May 23, 2017 → Aug 12, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11040035B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | Chemistry; Metallurgy | 0 | Active |
| US11591311B2 | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | Human Necessities | 0 | Active |
| US11304946B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | Chemistry; Metallurgy | 0 | Active |
| US11517622B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | Human Necessities | 0 | Active |
| US11795164B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11655297B2 | ILDR2 antagonists and combinations thereof | Chemistry; Metallurgy | 0 | Active |
| US11459312B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | Human Necessities | 0 | Active |
| US11951166B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | Human Necessities | 0 | Active |
| US11524944B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.